{"id":11440,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:11:31","modified_gmt":"2025-10-04T08:11:31","slug":"hyperthermie-qualite-de-vie-qdv","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/fr\/hyperthermie-qualite-de-vie-qdv\/","title":{"rendered":"Impact de l&rsquo;hyperthermie sur la Qualit\u00e9 de Vie (QdV) : Soulagement de la douleur, r\u00e9duction de la fatigue et avantages immunologiques adjuvants"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Impact de l'hyperthermie sur la Qualit\u00e9 de Vie (QdV) : Soulagement de la douleur, r\u00e9duction de la fatigue et avantages immunologiques adjuvants\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrul Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hyperthermie, Oncologie, essai clinique de Phase III, QdV, douleur,E-E-A-T\"\n      \/*... Le Sch\u00e9ma FAQPage serait ajout\u00e9 s\u00e9par\u00e9ment pour la section Questions Fr\u00e9quemment Pos\u00e9es *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autorit\u00e9 et Expertise (EEAT) : <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Par <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/fr\/docteur-en-hyperthermie-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, et <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/fr\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Impact de l&rsquo;hyperthermie sur la Qualit\u00e9 de Vie (QdV) : Soulagement de la douleur, r\u00e9duction de la fatigue et avantages immunologiques adjuvants<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">En oncologie moderne, la gestion du cancer vise l&rsquo;\u00e9quilibre optimal entre<a href=\"https:\/\/andromedichyperthermia.com\/fr\/hyperthermie-survie-patients-cancer\/\"> la Survie (OS\/DFS)<\/a> et <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">la Qualit\u00e9 de Vie (QdV).<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> L&rsquo;hyperthermie (HT) repr\u00e9sente une modalit\u00e9 adjuvante unique, d\u00e9montr\u00e9e par des essais cliniques majeurs ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/fr\/hyperthermie-oncologie-etudes-de-phase-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">ECA de Phase III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) pour am\u00e9liorer la QdV sur plusieurs plans : contr\u00f4le des sympt\u00f4mes, \u00e9tat fonctionnel g\u00e9n\u00e9ral et un excellent profil de s\u00e9curit\u00e9.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Avantage Palliatif Majeur : Contr\u00f4le de la Douleur (preuves de niveau A1 issues d&rsquo;essais cliniques de Phase III)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">La douleur osseuse m\u00e9tastatique d\u00e9grade la QdV. L&rsquo;Hyperthermie RF Locor\u00e9gionale, combin\u00e9e \u00e0 la Radioth\u00e9rapie (RT), offre un contr\u00f4le palliatif sup\u00e9rieur, selon <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">l&rsquo;\u00e9tude Phase III publi\u00e9e par Chi MS et coll<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Indicateur QdV\/Am\u00e9lioration de la Douleur<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT seule<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hyperthermie (HT)<\/span><\/span><\/th>\n<th>Impact QdV<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Taux de R\u00e9ponse Compl\u00e8te (CR) \u00e0 3 Mois<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (score de douleur z\u00e9ro)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Augmentation de 533 % des chances d&rsquo;\u00e9limination totale de la douleur.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dur\u00e9e du Soulagement de la Douleur<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u00e9diane: 55 jours\/7,9 semaines<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u00e9diane: Non atteinte \u00e0 24 semaines<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">La dur\u00e9e du soulagement triple, r\u00e9duisant la d\u00e9pendance aux analg\u00e9siques.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">En <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024, Sahinbas et ses collaborateurs ont publi\u00e9 une \u00e9tude de phase III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> pour la douleur des m\u00e9tastases osseuses provenant principalement du cancer du sein et de la prostate en utilisant l&rsquo;hyperthermie WBHT wIRA en plus de la RT.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Selon cette \u00e9tude, le groupe trait\u00e9 uniquement par radioth\u00e9rapie (RT) pr\u00e9sentait la douleur la plus intense. L&rsquo;\u00e9tude a \u00e9t\u00e9 achev\u00e9e apr\u00e8s l&rsquo;inclusion d&rsquo;un total de 61 patients, 5 ans apr\u00e8s la premi\u00e8re inclusion (avril 2016 &#8211; f\u00e9vrier 2021). Finalement, le taux de CR dans le groupe RT + WBH a montr\u00e9 la diff\u00e9rence la plus significative avec la RT en monoth\u00e9rapie, respectivement 47,4% contre 5,3%, dans les 2 mois suivant le traitement (valeur P &lt; 0,05). Le temps jusqu&rsquo;au soulagement complet de la douleur \u00e9tait de 10 jours pour RT + WBH, tandis que le crit\u00e8re final n&rsquo;a pas \u00e9t\u00e9 atteint dans le groupe RT en monoth\u00e9rapie. La progression de la douleur ou la stabilit\u00e9 de la maladie ont \u00e9t\u00e9 observ\u00e9es chez la moiti\u00e9 des patients du groupe RT dans les 4 semaines suivant le traitement. Cependant, ce score \u00e9tait proche de z\u00e9ro chez les patients RT + WBHT dans les deux mois suivant le traitement.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Conclusions:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH plus RT ont d\u00e9montr\u00e9 des augmentations significatives du soulagement de la douleur et un temps de r\u00e9ponse plus court par rapport \u00e0 la RT seule chez les patients atteints de l\u00e9sions osseuses m\u00e9tastatiques.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Indicateur QdV\/Am\u00e9lioration de la Douleur<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT seule<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hyperthermie (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Impact QdV<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Taux de R\u00e9ponse Compl\u00e8te (CR) \u00e0 2 mois<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (score de douleur z\u00e9ro)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Augmentation de 894 %<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * des chances d&rsquo;\u00e9limination totale de la douleur.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Temps jusqu&rsquo;au soulagement complet de la douleur<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">n&rsquo;a pas \u00e9t\u00e9 atteint<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 jours<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">B\u00e9n\u00e9fice Significatif et Rapide<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dur\u00e9e du Soulagement de la Douleur\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u00e9diane: 28 jours\/4 semaines chez la moiti\u00e9 des patients<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u00e9diane: Non atteinte \u00e0 24 semaines<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">La dur\u00e9e du soulagement * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">est multipli\u00e9e par six<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, r\u00e9duisant la d\u00e9pendance aux analg\u00e9siques.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Am\u00e9lioration de l&rsquo;\u00c9tat Fonctionnel et R\u00e9duction de la Fatigue<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Le b\u00e9n\u00e9fice de l&rsquo;HT sur la QdV est directement mesurable par des questionnaires standardis\u00e9s (EORTC QLQ-C30), montrant une am\u00e9lioration de l&rsquo;\u00e9tat g\u00e9n\u00e9ral (Fonction Physique, Fatigue et Anxi\u00e9t\u00e9):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QdV Significativement Am\u00e9lior\u00e9e (hyperthermie RF modul\u00e9e mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Un essai clinique randomis\u00e9 sur l&rsquo;Hyperthermie RF Modul\u00e9e (mEHT) dans le Cancer du Col de l&rsquo;Ut\u00e9rus (CCC) a rapport\u00e9 une am\u00e9lioration significative des scores de QdV \u00e0 long terme, les patients signalant de meilleurs scores sur les \u00e9chelles de Fonction Physique et \u00c9motionnelle.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Contr\u00f4le de la Fatigue et Immunomodulation:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> L&rsquo;Hyperthermie du Corps Entier (WBHT) et l&rsquo;HT en g\u00e9n\u00e9ral influencent positivement la fatigue chronique (CRF) en modulant les cytokines pro-inflammatoires (IL-6, TNF-alpha). L&rsquo;HT aide \u00e9galement \u00e0 maintenir et \u00e0 am\u00e9liorer les scores sur les \u00e9chelles de Fonction Physique et \u00c9motionnelle \u00e0 long terme.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">R\u00e9cup\u00e9ration \u00c9motionnelle Rapide (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Apr\u00e8s des proc\u00e9dures chirurgicales majeures incluant l&rsquo;HT (HIPEC), la QdV \u00e9motionnelle a tendance \u00e0 s&rsquo;am\u00e9liorer rapidement, commen\u00e7ant d\u00e8s *3 mois apr\u00e8s l&rsquo;op\u00e9ration, d\u00e9passant souvent les niveaux de base.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Consolidation des Avantages de la QdV \u00e0 Long Terme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Les donn\u00e9es en pratique clinique r\u00e9elle et les essais cliniques dans les cancers avanc\u00e9s renforcent le r\u00f4le de l&rsquo;Hyperthermie dans la stabilisation et l&rsquo;am\u00e9lioration de la QdV \u00e0 long terme:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Impact Curatif \u00e0 12 Mois:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Une analyse approfondie des patients trait\u00e9s avec une intention curative (RCT + HT) a montr\u00e9 une am\u00e9lioration significative, maintenue sur une *p\u00e9riode de 12 mois, des scores sur les sous-\u00e9chelles de QdV \u00e9valuant la **Fonction \u00c9motionnelle, la Fonction Sociale* et *l&rsquo;Insomnie (SL)*, par rapport \u00e0 la population de r\u00e9f\u00e9rence oncologique de l&rsquo;EORTC .[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Avantages Palliatifs:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Dans un contexte palliatif, l&rsquo;ajout de l&rsquo;HT au traitement standard a conduit \u00e0 une am\u00e9lioration cliniquement pertinente de la *Douleur (PA)* et \u00e0 une r\u00e9duction des *Difficult\u00e9s Financi\u00e8res (FI)* *3 mois apr\u00e8s le traitement*, contribuant \u00e0 un meilleur \u00e9tat g\u00e9n\u00e9ral du patient .[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QdV Am\u00e9lior\u00e9e dans la Maladie Avanc\u00e9e (Cancer Colorectal):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Dans une \u00e9tude \u00e9valuant l&rsquo;Hyperthermie \u00e0 Haute Fr\u00e9quence assist\u00e9e par chimioth\u00e9rapie chez des patients atteints de Cancer Colorectal de stade interm\u00e9diaire et avanc\u00e9, le groupe recevant la combinaison a montr\u00e9 des scores de QdV significativement plus \u00e9lev\u00e9s (am\u00e9lior\u00e9s) apr\u00e8s 4 cycles de traitement, d\u00e9montrant que l&rsquo;HT am\u00e9liore effectivement la QdV, en plus des effets th\u00e9rapeutiques, tout en maintenant une meilleure s\u00e9curit\u00e9 .[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Avantages Biologiques Adjuvants et Index Th\u00e9rapeutique Sup\u00e9rieur<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">L&rsquo;HT maximise la l\u00e9talit\u00e9 du traitement sans augmenter significativement le risque de toxicit\u00e9 s\u00e9v\u00e8re (Grade 3-4), maintenant ainsi un Index Th\u00e9rapeutique \u00e9lev\u00e9:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">S\u00e9curit\u00e9 Valid\u00e9e (essais cliniques Phase III):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Les m\u00e9ta-analyses dans le Cancer du Col de l&rsquo;Ut\u00e9rus d\u00e9montrent aucune diff\u00e9rence significative dans la toxicit\u00e9 aigu\u00eb ou tardive (RR Toxicit\u00e9 1.01).[6] Le profil de s\u00e9curit\u00e9 est maintenu dans le Cancer Rectal[7] et dans les essais sur le Cancer du Pancr\u00e9as[8].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pr\u00e9servation des Organes:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Dans le Cancer Rectal, l&rsquo;ajout de l&rsquo;HT \u00e0 la chimioradioth\u00e9rapie n\u00e9oadjuvante augmente la Survie Sans Colostomie (CFS) \u00e0 5 ans de 69,0% \u00e0 87,7%, un b\u00e9n\u00e9fice fonctionnel majeur pour la QdV.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Effet Abscopal (Type Vaccin):<\/strong> L&rsquo;HT d\u00e9clenche la mort cellulaire immunog\u00e8ne, lib\u00e9rant des Prot\u00e9ines de Choc Thermique (HSPs) qui activent les cellules T CD8+ cytotoxiques. Cette amorce immunologique syst\u00e9mique contribue au contr\u00f4le de la maladie r\u00e9siduelle et est un avantage adjuvant essentiel.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Conclusion: Th\u00e9rapie Ax\u00e9e sur le Patient<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">L&rsquo;int\u00e9gration de l&rsquo;Hyperthermie dans le protocole oncologique repr\u00e9sente une strat\u00e9gie avanc\u00e9e, bas\u00e9e sur des preuves cliniques, qui non seulement am\u00e9liore la Survie, mais fournit \u00e9galement un contr\u00f4le robuste des sympt\u00f4mes et maintient la Qualit\u00e9 de Vie. Le soulagement de la douleur, le contr\u00f4le de la fatigue et un excellent profil de s\u00e9curit\u00e9 font de l&rsquo;HT un \u00e9l\u00e9ment essentiel des soins holistiques du patient oncologique.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nous vous invitons \u00e0 consulter nos experts pour int\u00e9grer l&rsquo;Hyperthermie dans votre protocole, dans le but de maximiser \u00e0 la fois l&rsquo;efficacit\u00e9 et la Qualit\u00e9 de Vie.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Assurance EEAT:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ce contenu est bas\u00e9 sur des donn\u00e9es publi\u00e9es issues d&rsquo;essais cliniques randomis\u00e9s de Phase III et prospectifs, utilisant des instruments standard de mesure de la Qualit\u00e9 de Vie (EORTC QLQ-C30). Les r\u00e9f\u00e9rences compl\u00e8tes sont int\u00e9gr\u00e9es avec des liens directs vers les publications sources.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">R\u00e9f\u00e9rences:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autorit\u00e9 et Expertise (EEAT) : Par Dr. Veronica Iatan , MD, et Cristian Gologan M.Sc , Andromedichyperthermia Impact de l&rsquo;hyperthermie sur la Qualit\u00e9 de Vie (QdV) : Soulagement de la douleur, r\u00e9duction de la fatigue et avantages immunologiques adjuvants En oncologie moderne, la gestion du cancer vise l&rsquo;\u00e9quilibre optimal entre la Survie (OS\/DFS) et la&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[106,23,911],"tags":[912,1047,913,1045,914,122,293,1046,918],"class_list":["post-11440","post","type-post","status-publish","format-standard","hentry","category-actualites","category-non-categorise","category-studii-clinice-fr","tag-calitatea-vietii-fr","tag-douleur","tag-durere-fr","tag-essai-clinique-de-phase-iii","tag-hipertermie-oncologica-fr","tag-hyperthermie-fr","tag-oncologie","tag-qdv","tag-studii-faza-iii-fr"],"gutentor_comment":1,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/posts\/11440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/comments?post=11440"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/posts\/11440\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/media?parent=11440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/categories?post=11440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/tags?post=11440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}